This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

CARTemis Therapeutics GmbH


CARTemis Therapeutics is a spin-off of the Max Delbrück Center in Berlin, developing novel CAR T cell therapies to market-ready products with regulatory approval. Its portfolio consists of highly developed and differentiated CAR T-cell products using unique modes of action to overcome obstacles limiting durable success of CAR T cells in life-threatening hematologic malignancies. The two lead products are currently evaluated in publicly funded phase 1/2 academic clinical trials in Germany.